Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any - 30 |
| Updated: | 5/19/2016 |
| Start Date: | December 2009 |
Genetic Predictors of AML Treatment Response
This research trial studies deoxyribonucleic acid (DNA) in blood or bone marrow samples from
younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from
patients with cancer in the laboratory may help doctors learn more about changes that occur
in DNA and identify biomarkers related to cancer. It may also help doctors predict how well
patients will respond to treatment.
younger patients with acute myeloid leukemia. Studying samples of blood and bone marrow from
patients with cancer in the laboratory may help doctors learn more about changes that occur
in DNA and identify biomarkers related to cancer. It may also help doctors predict how well
patients will respond to treatment.
PRIMARY OBJECTIVES:
l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML)
relapse and infection risk.
II. Validate positive associations seen in the genome-wide scan with a fine mapping
approach.
III. Perform simulated clinical trials using germline genetic variation data to test the
feasibility of using genetic data to inform the clinical care of pediatric patients with
AML.
OUTLINE:
Germline DNA is obtained from previously collected peripheral blood or bone marrow samples
for array-based genotyping studies, including genome-wide association studies (single
nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are
performed to test the clinical applicability of using genetic variation data in the
management of infectious complications.
l. Perform a genome-wide scan to test for loci associated with acute myeloid leukemia (AML)
relapse and infection risk.
II. Validate positive associations seen in the genome-wide scan with a fine mapping
approach.
III. Perform simulated clinical trials using germline genetic variation data to test the
feasibility of using genetic data to inform the clinical care of pediatric patients with
AML.
OUTLINE:
Germline DNA is obtained from previously collected peripheral blood or bone marrow samples
for array-based genotyping studies, including genome-wide association studies (single
nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are
performed to test the clinical applicability of using genetic variation data in the
management of infectious complications.
Inclusion Criteria:
- Diagnosis of AML
- In remission
- Adequate DNA from peripheral blood or bone marrow samples
- Concurrent enrollment on CCG-2961, COG-AAML03P1, COG-AAML0531, AML-93, AML-97,
AML-04,AML-09, or Canada AML Infection clinical trial required
We found this trial at
1
site
Click here to add this to my saved trials
